Notice of Proposed Sale · 144
Legend Biotech Corp
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Legend Biotech Corp
- Issuer CIK
- 0001801198
- SEC file number
- 001-39307
- Phone
- 732-850-5598
- Person for whose account securities are to be sold
- Huang Ying
- Relationships to issuer
- Former Officer & Director
- Street
- 2101 COTTONTAIL LANE
- City
- SOMERSET
- State / country code
- NJ
- Postal code
- 08873
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| American depositary shares | 69,812 | 1,302,109.37 | 369,886,369 | 09/22/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| American depositary shares | 09/22/2026 | Stock Option Exercise | Issuer | 69,812 | N | 09/22/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Ying Huang | American depositary shares | 06/26/2026 | 2,783 | 79,016.88 |
Seller — prior-sale row 1, entry 1
- Name
- Ying Huang
- Street
- 2101 Cottontail Lane
- City
- Somerset
- State / country code
- NJ
- Postal code
- 08873
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 09/22/2026
- Signed
- /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ying Huang
Company context
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.